The company is located in No. 376 Yanzihe Road, Hefei High-tech Zone, covering an area of 80 mu with a registered capital of 145 million RMB, it passed the new GMP certification in 2014 as a national designated manufacturer of blood products and has nearly 400 employees.

Blood products are mainly bioactive preparations sourced from plasma of healthy human and prepared by using biological process or separation and purification technology, including albumin, immunoglobulin and various coagulation factors, etc. In medical emergencies and the prevention and treatment of certain specific diseases, the blood product plays an irreplaceable role compared to other drugs.

The mainly blood products of the company include human albumin, human immunoglobulin, human immunoglobulin (pH4) for intravenous injection, human immunoglobulin (pH4) for intravenous injection, freeze-dried, hepatitis B human immunoglobulin, human tetanus immunoglobulin, human rabies immunoglobulin, coagulation factor VIII, and prothrombin complex concentrate (human), freeze dried. After years of development, the overall strength of the company ranks among the top four in China, and the overall production and sales volume of special immune products ranks the first in China, which has formed obvious brand, quality and management advantages. 

Plasma is the core resource of blood product enterprises, and plasma donation centers is an institution specializing in plasma collection set up by laws. The company now has eighteen plasmapheresis subsidiaries located in Anhui Province, Guangdong Province, Inner Mongolia, Zhejiang Province and Hainan Province, with the number of plasma centers ranking among the top three in the same industry in China, providing about 1,000 job opportunities.

In order to better serve customer patients and provide high quality products, the company has introduced more than 30 sets of advanced equipment such as imported German Bestwagreen filter press, German Millipore ultrafiltration machine, German Doctor bottle washing machine and filling machine, German B+S automatic syringe spinning rod and labeling machine.

Tonrol Biopharmaceutical pays attention to the growth of every partner, respects the staff, cares for them and promotes their skills. The company creates a harmonious and positive cultural atmosphere through colorful collective activities and sundry training for employees, and continues to carry out activities such as staff tourism, tea party, GMP knowledge contest and staff training, etc. Since 2016, the company has set up an employee support fund to extend a helping hand to struggling employees and other people in need. As of 2017, hundreds of thousands of Yuan have been donated to give warmth to employees in need.

In 2013, the company was acquired by Shanghai RAAS Blood Products Co., Ltd. and became its wholly owned subsidiary.  As a key biopharmaceutical enterprise in Henan Province, Zhengzhou RAAS is a blood products manufacturer integrating product research and development, production and sales.

Since its establishment, the company has continuously enhanced its independent research and development and innovation capability, and has 7 serial numbers for 4 kinds of products, with an annual processing capacity of 200 tons of plasma. It has been recognized as "Sub-station of Postdoctoral Scientific Research Workstation in Zhengzhou High-tech Industrial Development Zone", "Provincial Enterprise Technology Center" and "Henan Province Protein Drug Engineering Products Research Center". The company has two plasmapheresis centers with annual plasma collection capacity of 120 tons. The plasma collection capacity of each center is at the leading level across the sector.

Zhengzhou RAAS always insists on "integrity-based", with the spirit of "honesty, pragmatism, self-discipline and innovation", taking the market as the guide, and "creating a happy life" as the establishment policy, and leveraging the company's advantages in technology, talents, management and information so as to make contributions to the national medical and health care industry thereby achieving a win-win situation for both corporate and social benefits.

In June 2016, Haikang Biopharmaceutical passed the new national GMP certification. The main products include human albumin, human immunoglobulin for intravenous injection, hepatitis B human immunoglobulin, and human immunoglobulin for intramuscular injection, among which: human albumin and human immunoglobulin for intravenous injection are high-tech products of Zhejiang Province.

Located in No. 28, Yangxin Road, Lucheng District, Wenzhou City, Zhejiang Province. Haikang Biopharmaceutical was formed in June 1996 as a joint venture according to the spirit of WEN ZHENG JI [1996] No. 44 document of the Wenzhou Municipal Government by Wenzhou Conch Industrial Group Corporation (now renamed as Wenzhou Conch Group Co., Ltd., referred to as Conch Group) and Zhejiang Blood Products Institute. In March 2006, after Zhejiang Blood Products Institute completed its institutional restructuring, Haikang Biopharmaceutical became a wholly-owned subsidiary of Conch Group. In December 2016, the company completed the equity restructuring and became a holding subsidiary of Tonrol Biopharmaceutical Co., LTD., a subsidiary of the listed company Shanghai RAAS Blood Products Co., LTD.

Haikang Biopharmaceutical (including plasma centers) has more than 200 employees. It has three single-collection plasma donation center (wholly-owned subsidiaries): Panan Haikang  plasma donation center, Wencheng Haikang plasma donation center and Qingtian Haikang plasma donation center, which undertake the plasma collection task of the company.

Since the GMP certification in 1998, Haikang Biopharmaceutical has taken it seriously for the quality training of its staff and has been consistently implementing a full staff training system. Every year, it makes a training plan according to the requirements of GMP and organize business learning for employees. In order to make every employee fully aware of the important role of an advanced software management system in enterprise management, the company has formulated a set of Quality Management Standards for Production of Haikang Biopharmaceutical Blood Products according to the requirements of Good Manufacturing Practice of Medical Products, which covers the management standards, technical standards, operation techniques and record certificates of production, technology, quality assurance, quality control and other functional departments of Haikang Biopharmaceutical. 

The fittest survive natural selection. The competition among enterprises is actually the competition of market, while the competition of market is the competition of products, and further the competition of products is mainly the competition of technology, and finally the competition of technology is the competition of talents. Haikang Biopharmaceutical will continue to improve the overall competitiveness of the enterprise, lead all "Haikang staff" to operate in accordance with GMP standards, and strictly implement relevant national laws and regulations, thus striving to promote the business development of the enterprise and create a brighter future for Haikang with a new look in spirit of "standardization, pragmatism, breakthrough and innovation".